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PURPOSE. To investigate the effects of central corneal thickness
(CCT)-associated variants on primary open-angle glaucoma
(POAG) risk using single nucleotide polymorphisms (SNP) data
from the Glaucoma Genes and Environment (GLAUGEN) and
National Eye Institute (NEI) Glaucoma Human Genetics
Collaboration (NEIGHBOR) consortia.
METHODS. A replication analysis of previously reported CCT
SNPs was performed in a CCT dataset (n ¼ 1117) and these
SNPs were then tested for association with POAG using a larger
POAG dataset (n¼6470). Then a CCT genome-wide association
study (GWAS) was performed. Top SNPs from this analysis were
selected and tested for association with POAG. cDNA libraries
from fetal and adult brain and ocular tissue samples were
generated and used for candidate gene expression analysis.
RESULTS. Association with one of 20 previously published CCT
SNPs was replicated: rs12447690, near the ZNF469 gene (P¼
0.001; b ¼ 5.08 lm/allele). None of these SNPs were
significantly associated with POAG. In the CCT GWAS, no
SNPs reached genome-wide significance. After testing 50
candidate SNPs for association with POAG, one SNP was
identified, rs7481514 within the neurotrimin (NTM) gene, that
was significantly associated with POAG in a low-tension subset
(P ¼ 0.00099; Odds Ratio [OR] ¼ 1.28). Additionally, SNPs in
the CNTNAP4 gene showed suggestive association with POAG
(top SNP ¼ rs1428758; P ¼ 0.018; OR ¼ 0.84). NTM and
CNTNAP4 were shown to be expressed in ocular tissues.
CONCLUSIONS. The results suggest previously reported CCT loci
are not significantly associated with POAG susceptibility. By
performing a quantitative analysis of CCT and a subsequent
analysis of POAG, SNPs in two cell adhesion molecules, NTM
and CNTNAP4, were identified and may increase POAG
susceptibility in a subset of cases. (Invest Ophthalmol Vis
Sci. 2012;53:4468–4474) DOI:10.1167/iovs.12-9784
From the 1Duke University Center for Human Genetics, Durham, North Carolina; the 2Department of Human Genetics, University of
Michigan, Ann Arbor, Michigan; the 3Vanderbilt University School of Medicine, Center for Human Genetics Research, Nashville, Tennessee; the
Departments of 4Ophthalmology and Visual Sciences and 5Epidemiology, University of Michigan, Ann Arbor, Michigan; the 6Department of
Ophthalmology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; the 7Department of Ophthalmology, Johns
Hopkins University School of Medicine, Baltimore, Maryland; the 8Eye Doctors of Washington DC, Washington, DC; the 9Channing Laboratory,
Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; the 10Department of Ophthalmology, University of Miami,
Miami, Florida; the 11Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts; the
12Department of Human Genetics, University of Miami School of Medicine, Miami, Florida; the 13Department of Ophthalmology, West Virginia
University School of Medicine, Morgantown, West Virginia; the 14Department of Ophthalmology, University of Pittsburgh, Pittsburgh,
Pennsylvania; the 15Department of Ophthalmology, Stanford University, Palo Alto, California; the 16Department of Genetics, Stanford University,
Palo Alto, California; the 17Department of Ophthalmology, University of California, San Diego, California; and the 18Department of
Ophthalmology, Duke University School of Medicine, Durham, North Carolina.
Supported by National Eye Institute Grant HG005259-01 (JLW); the GENEVA project Grant HG004728 (LRP) and U01-HG004424 (Broad
Institute); the National Eye Institute through ARRA Grants 3R01EY015872-05S1 (JLW) and 3R01EY019126-02S1 (MAH); the NIH Grants
EY015543 (RRA), EY006827 (DG), EY13315 and EY019126 (MAH), CA87969, CA49449, and CA55075 (JHK), EY009149 (PL), EY015473 (LRP),
EY012118 (MPV), EY015682 (AR), EY011671 and EY09580 (JER), EY013178 (JS), RR015574, EY015872, EY010886, and EY009847 (JLW),
EY014685 (TY), EY011008, EY144428, EY144448, and EY18660 (KZ); the Harvard Glaucoma Center for Excellence, and the Margolis Fund
(JLW and LRP); in part by the NIH T32EY021453 (BLY); the Glaucoma Research Foundation, American Health Assistance Foundation, and the
Glaucoma Foundation (YL); the Research to Prevent Blindness (JLW, LRP, TY, and JER); and in part by Duke University’s CTSA Grant 1 UL1
RR024128-01 from NCRR/NIH.
Submitted for publication March 2, 2012; revised May 2, 2012; accepted May 22, 2012.
Disclosure: M. Ulmer, None; J. Li, None; B.L. Yaspan, None; A.B. Ozel, None; J.E. Richards, None; S.E. Moroi, None; F. Hawthorne,
None; D.L. Budenz, None; D.S. Friedman, None; D. Gaasterland, None; J. Haines, None; J.H. Kang, None; R. Lee, None; P. Lichter,
None; Y. Liu, None; L.R. Pasquale, None; M. Pericak-Vance, None; A. Realini, None; J.S. Schuman, None; K. Singh, None; D. Vollrath,
None; R. Weinreb, None; G. Wollstein, None; D.J. Zack, None; K. Zhang, None; T. Young, None; R.R. Allingham, None; J.L. Wiggs,
None; A. Ashley-Koch, None; M.A. Hauser, None
Corresponding author: Michael A. Hauser, Center for Human Genetics, Duke University Medical Center, Box 3445, Durham, NC 27710;
mike.hauser@duke.edu.
Investigative Ophthalmology & Visual Science, July 2012, Vol. 53, No. 8
4468 Copyright 2012 The Association for Research in Vision and Ophthalmology, Inc.
The cornea is a highly collagenous, transparent tissue that isa continuation of the sclera, which posteriorly supports
the optic nerve. A reduction in central corneal thickness (CCT)
has been observed in a number of systemic and ocular diseases,
including Ehlers-Danlos syndrome, osteogenesis imperfecta,
keratoconus, and brittle cornea syndrome.1–4 Reduced CCT
has also been associated with an increased risk of primary
open-angle glaucoma (POAG), the second leading cause of
blindness worldwide.5,6 In POAG, CCT has been shown to be a
risk factor independent of other known risk factors, including
advanced age and elevated intraocular pressure (IOP), and has
been linked with increased disease severity and rapid disease
progression.5–8
Due to the strong association observed between CCT and
POAG, elucidating the genetics of CCT may lead to identifica-
tion of novel POAG risk genes, and could improve the
understanding of the molecular mechanism driving this
association. CCT has previously been shown to be a highly
heritable, normally distributed quantitative trait with heritabil-
ity estimates as high as 95%.5 Several studies have been
successful in identifying CCT loci through candidate gene and
genome-wide approaches. An Australian and UK cohort study
first identified the ZNF469 gene, an uncharacterized zinc-finger
protein, and FOXO1, a member of the forkhead family of
transcription factors, in a genome-wide analysis of CCT.2 The
ZNF469 locus has been replicated in follow-up studies in
Croatian, Scottish, and multiple Asian populations.3,4,9 Consis-
tent with the belief that CCT is a complex quantitative trait
with multigenic inheritance, these studies have also identified
numerous other loci in genomic regions containing collagen V
alpha-1 (COL5A1), collagen VIII alpha-2 (COL8A2), A-kinase
anchor protein 13 (AKAP13), inhibitor of Bruton’s tyrosine
kinase (IBTK), leucine-rich repeat kinase 1 (LRRK1), as well as
multiple intergenic regions.3,4,9
Although these genome-wide studies have successfully
identified genetic variants associated with CCT, they have
been performed in primarily nonglaucomatous population
cohorts. Because of the strong correlation of reduced CCT and
increased POAG risk, it is possible that POAG cases have
additional variants associated with CCT compared with normal
populations, and that these variants may explain the underly-
ing molecular mechanism driving the association between
reduced CCT and POAG risk. Identification of complex disease
genes through quantitative endophenotypes has many advan-
tages, and has been successful in POAG with other quantitative
risk factors.10–12 In this study, an investigation of the effects of
previously reported CCT-associated variants and a genome-
wide analysis of CCT was performed in a primarily POAG case
population. The effects of these SNPs were then tested using a
larger POAG case-control population.
MATERIALS AND METHODS
Study Population
Genome-wide genotype data were available from two separate cohort
studies: the Glaucoma Genes and Environment (GLAUGEN) study
(dbGaP Study Accession: phs000308.v1.p1, available at http://www.
ncbi.nlm.nih.gov/projects/gap), which is part of the Gene, Environ-
ment Association Study consortium, and the National Eye Institute (NEI)
Glaucoma Human Genetics Collaboration (NEIGHBOR) study.13,14 The
GLAUGEN study included Caucasian POAG cases and controls selected
from three different sub studies: the Nurses’ Health Study, the Health
Professionals Follow-up Study, and the Genetics Etiologies of Primary-
Open Angle Glaucoma Study. This study was approved by the
institutional review boards of the Massachusetts Eye and Ear infirmary,
the Harvard University School of Public Health and the Brigham and
Woman’s Hospital. The NEIGHBOR study consists of Caucasian POAG
cases and controls collected from 12 different study sites. Each
individual study was approved by their respective institutional review
boards (see Supplementary Material and Supplementary Table S1,
http://www.iovs.org/lookup/suppl/doi:10.1167/iovs.12-9784/-/
DCSupplemental). All human subjects’ research adhered to the tenets of
the Declaration of Helsinki. POAG cases for both studies were defined as
individuals with glaucomatous optic neuropathy with reproducible
visual field tests or a cup-to-disc ratio of greater than or equal to 0.7 in at
least one eye. POAG cases were grouped into two subsets based on IOP
for stratified analyses. A low-tension subset was defined by an IOP of
less than or equal to 21 mmHg at the time of sample collection, with no
history of IOP greater than 21 mmHg (either by self report or by chart
review). A total of 705 POAG cases met the low-tension definition while
1629 POAG cases with a history of any IOP greater than 21 mmHg were
included in the high-tension subset. POAG controls had normal IOP (<
21 mmHg), no evidence of visual field loss, and a normal cup-to-disc
ratio (< 0.6).
CCT Association Analysis
CCT measurements were available for 851 individuals, both POAG
cases and POAG controls, from the NEIGHBOR study, and 325
individuals, all POAG cases, from the GLAUGEN study (see Supple-
mentary Material and Supplementary Table S1, http://www.iovs.org/
lookup/suppl/doi:10.1167/iovs.12-9784/-/DCSupplemental). For the
CCT analysis, the mean CCT from both eyes was used as the analysis
outcome variable because a strong correlation between right eye CCT
and left eye CCT (R2¼0.92 in GLAUGEN; R2¼0.83 in NEIGHBOR) was
observed. Ten outliers in GLAUGEN and 16 outliers in NEIGHBOR,
which were defined by large left-right differences (beyond 2.5 SD of
the overall distribution of left-right differences) were removed from the
analysis. A lack of left-right eye correlation could be due to true right
and left eye CCT differences, measurement artifacts, or unknown
corneal defects. Additionally, individuals with known corneal diseases,
noncaucasian ancestry, and one distribution outlier with an extremely
small average CCT value (< 374 lm) were removed. Population
substructure was assessed by principal components analysis performed
using Eigenstrat15 and genetic outliers were removed from the analysis
(see Supplementary Material and Supplementary Fig. S1, http://www.
iovs.org/lookup/suppl/doi:10.1167/iovs.12-9784/-/DCSupplemental).
After data cleaning, the CCT dataset consisted of 1,117 individuals,
including 668 POAG cases and 144 POAG controls from the
NEIGHBOR study, and 305 POAG cases from the GLAUGEN study
(Table 1).
CCT distribution differences were assessed among a variety of
clinical variables, including POAG case status, CCT measurement
device, DNA source (blood versus cheek), DNA extraction method
TABLE 1. Population Characteristics of the CCT Dataset
CCT Dataset n Mean (SD)
Total 1117
Age (y) 61.6 (12.58)
Sex (% male) 48.9%
CCT (lm)
*POAG control 144 557.7 (33.80)
*POAG case 973 545.9 (35.85)
*Standard pachymeter 1010 545.6 (35.33)
*Portable pachymeter 107 565.0 (35.60)
*POAG cases, low IOP subset 307 541.8 (36.10)
*POAG cases, high IOP subset 625 548.4 (35.87)
* Student’s t-test shows statistically significant differences were
observed when comparing CCT distributions between: POAG cases
versus controls; CCT measurements made by a standard pachymeter
versus a portable model; and POAG cases within the low- versus high-
tension subsets.
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(Qiagen, DNAzol, GENTRA), history of laser trabeculoplasty, and
incisional glaucoma filtration surgery using the Student’s t-test
calculated in SAS (version 9.2; SAS Institute Inc., Cary, NC).
Genotyping was performed using the Human660W-Quad v1
BeadChip (Illumina, Inc., San Diego, CA) array for both the NEIGHBOR
and GLAUGEN studies. SNPs with a missing call rate of greater than 2%
and SNPs out of Hardy-Weinberg equilibrium in the control population
(P < 104) were removed from the analysis. The final dataset contained
480,304 cleaned SNPs shared between the two studies. SNPs were
tested for association with average CCT using linear regression
performed in PLINK,16 adjusted for age, sex, instrument used to
measure CCT, and POAG case/control status.
POAG Association Analysis
Candidate SNPs were tested for association with POAG risk in the full
NEIGHBOR and GLAUGEN datasets. After quality control filtering,
including removal of sex mismatches, duplicate samples, and
population outliers, the final dataset contained 2125 POAG cases and
2251 POAG controls from the NEIGHBOR study, and 964 POAG cases
and 1130 POAG controls from the GLAUGEN study. In the NEIGHBOR
study, logistic regression models included age, sex, collection site, and
four principal components as covariates. In the GLAUGEN study, the
method of DNA extraction, the specimen type (blood versus cheek),
and site were found to be independently associated with both DNA
quality and POAG case/control status, and were included in logistic
regression models along with age, sex, and six principal components. A
formal meta-analysis of the two studies was conducted in PLINK.16
POAG risk was assessed in the overall dataset, the low-tension subset,
and the high-tension subset.
Gene Expression Analysis
cDNA was prepared from human, adult and fetal brain and ocular tissue
samples to determine the presence of candidate gene expression. Adult
and fetal brain cDNA libraries were generated from the Human Total
RNA Master Panel II (Clontech Laboratories, Inc., Mountain View, CA).
A fetal ocular sample from a 24 week gestation period was obtained
from Advanced Biosciences Resources (Alameda, CA) and was
preserved in RNAlater (Qiagen, Inc., Valencia, CA) within minutes of
collection. An adult eye was provided from the North Carolina Eye
Bank (Winston-Salem, NC). This sample was collected 5 hours and 10
minutes postmortem and was preserved in RNAlater (Qiagen). The
cornea, optic nerve, and sclera wall was dissected from each eye. The
cornea was isolated using a 5-mm biopsy punch at the center of the
cornea, optic nerve samples were collected using dissection scissors,
and the scleral tissue was isolated using a 7-mm biopsy punch centered
behind the fovea. To reduce retinal contamination of the scleral
sample, a second 5-mm biopsy was taken from the center of the 7-mm
punch after complete removal of the retina. mRNA was extracted from
each tissue sample independently using a total RNA extraction kit
(Ambion mirVana; Ambion, Austin, TX). Quality control for each
sample included measuring RNA concentration and RNA subunit ratios
at 260/280 nm using Nanodrop technology (Invitrogen, Carlsbad, CA).
cDNA was generated from each mRNA library using a synthesis kit
(SuperScript III First-Strand Synthesis kit; Invitrogen).
The brain, cornea, optic nerve, and sclera cDNA libraries were used
to perform PCR assays to determine the presence or absence of
contactin-associated protein-like 4 (CNTNAP4) and neurotrimin (NTM)
gene expression. The PCR assays contained 2 lL cDNA, 1 3 PCR buffer,
200 lmol/each dNTP, 1.5 mM MgCl2, 200 ng of the forward primer, 200
ng of the reverse primer, and 3 U of Taq polymerase (Platinum Taq DNA
polymerase; Invitrogen). Primers were designed using Primer317 and
spanned intron-exon boundaries. CNTNAP4 was amplified using the
forward primer 50 AGG ATA CTG CAC TGG CAG GT 30 and reverse
primer 50 TGC TGA TAA ATG CGA ACA GC 30 and NTM was amplified
using the forward primer 50 TGG CTT TGT GAG TGA AGA CG 30 and
the reverse primer 50 AGG CCA CGC AAG TGT AGT TC 30. The
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was used
as a control to check for cDNA quality, and was amplified using the
forward primer 50 CGA CCA CTT TGT CAA GCT CA 30 and the reverse
primer 50 AGG GGT CTA CAT GGC AAC TG 30. The products were
amplified using a touchdown PCR protocol under the following
conditions: 948C for 3 minutes; 2 cycles of 948C for 5 seconds, 618C for
30 seconds, and 728C for 30 seconds repeated using an incremental
28C decrease in annealing temperature until 518C was reached;
followed by 30 cycles with a 518C annealing temperature; and a final
extension at 728C for 3 minutes. The PCRs were purified (PureLink
Quick Gel Extraction Kit; Invitrogen) and the products were verified by
sequencing at Eton Bioscience, Inc. (Durham, NC). The results were
visualized on an ethidium bromide stained, 1.5% agarose gel.
RESULTS
The CCT between POAG cases and controls was significantly
different (P¼0.0002), with a mean (SD) of 557.7 (33.80) lm in
POAG controls and 545.9 (35.85) lm in POAG cases (Table 1).
A significant difference (P ¼ 0.008) in the distribution of CCT
was observed between the low-tension compared with high-
tension POAG cases (Table 1). The high-tension subset had a
mean CCT of 548.4 (35.87) lm, while the low-tension POAG
cases had a mean CCT of 541.8 (36.10) lm. The instrument
used to measure CCT (ultrasound table unit versus a portable
handheld unit; DGH Technology, Inc., Exton, PA) had a
significant effect on mean CCT (P < 0.0001; Table 1). Within
the CCT dataset, history of laser trabeculoplasty and glaucoma
filtration surgery was available for 422 POAG cases. There was
no difference in CCT between individuals with or without a
history of laser trabeculoplasty (P ¼ 0.86) or glaucoma
filtration surgery (P ¼ 0.62).
Twenty previously published CCT SNPs (Table 2) were
tested for association with CCT in the NEIGHBOR/GLAUGEN
CCT dataset (n ¼ 1117). Using a Bonferroni multiple testing
correction significance threshold of 0.05/20¼0.0025, one SNP,
rs12447690 upstream of ZNF469 (P ¼ 0.001, b ¼5.08 lm/
allele) showed significant evidence of association with CCT.
Three additional SNPs showed suggestive evidence of associ-
ation: rs7044529 in COL5A1 (P¼ 0.003, b¼6.58 lm/allele),
rs1536478 in the RXRA/COL5A1 intergenic region (P¼ 0.004,
b¼ 4.47 lm/allele), and rs1538138 near IBTK (P¼ 0.004, b¼
4.98 lm/allele) (Table 2). The direction and the effect size of
these four variants are consistent with previous reports.2–4,9
These 20 SNPs were then tested for association with POAG
case/control status in the larger NEIGHBOR/GLAUGEN meta-
analysis in the overall dataset (n ¼ 6470), low-tension (n ¼
4086), and high-tension (n ¼ 4966) subsets. Using the same
significance threshold as above (0.0025), none of these SNPs
showed any evidence of association with POAG (Table 2).
Next, a CCT genome-wide association study (GWAS) was
performed in order to identify novel candidate SNPs using the
CCT dataset. No SNP met a genome-wide significance
threshold of 1 3 107 (Fig. 1), either in the overall dataset or
when the analysis was confined to only POAG cases. The top
five most significant SNPs (Fig. 1, and see Supplementary
Material and Supplementary Table S2, http://www.iovs.org/
lookup/suppl/doi:10.1167/iovs.12-9784/-/DCSupplemental)
were located on chromosome (Chr.) 2 at PRKCE (rs10205024;
P ¼ 1.68 3 106; b ¼ 7.49 lm/allele); on Chr. 16 at the
CNTNAP4 gene (rs9939043; P ¼ 2.70 3 106; b ¼ 7.15 lm/
allele); on Chr. 20 at the HAO1 gene (rs2423322; P ¼ 4.48 3
106; b¼9.03 lm/allele); in an intergenic region on Chr. 7 at
the EMID2/MYL10 locus (rs17135662; P ¼ 8.69 3 106; b ¼
8.31 lm/allele); and on Chr. 11 at the NTM gene (rs7108536; P
¼ 1.00 3 105; b ¼6.78 lm/allele).
4470 Ulmer et al. IOVS, July 2012, Vol. 53, No. 8
The 50 SNPs most strongly associated with CCT were
selected from the GWAS results based on a P value cut off of 1
3 104 and tested for association with POAG risk using the
overall NEIGHBOR/GLAUGEN meta-analysis and meta-analyses
stratified by IOP. Using a significance threshold of P  0.001
(Bonferroni correction of 0.05/50), one SNP at the NTM gene
locus (rs7481514, P ¼ 0.00099, OR ¼ 1.28) was significantly
associated with POAG in the low-tension subset (Table 3). As
FIGURE 1. Manhattan plot showing the results of the linear regression analysis for CCT in the NEIGHBOR/GLAUGEN CCT dataset. The red line
(upper) indicates the genome-wide significance threshold (P¼1 3 107), the blue line (middle) indicates the suggestive significance threshold (P¼
1 3 105), and the black line (lower) indicates the threshold level selected for follow up POAG association analysis (P ¼ 1 3 104). A quantile-
quantile plot of the resulting P values is shown in Supplementary Figure S2 (see Supplementary Material and Supplementary Fig. S2, http://www.
iovs.org/lookup/suppl/doi:10.1167/iovs.12-9784/-/DCSupplemental).
TABLE 2. Top Ten SNPs Associated with POAG in the Low-Tension Subset
SNP2–4,9 Chr. Locus
CCT Analysis (n ¼ 1117) POAG Analysis Overall Dataset (n ¼ 6470)
D lm/Minor Allele P OR P
rs3767703 1 Col8A2 2.37 0.37 0.95 0.51
rs7550047 1 Col8A2 2.78 0.27 0.98 0.78
rs96067 1 Col8A2 0.83 0.66 0.94 0.20
rs11694554 2 Col4A3 3.82 0.10 1.14 0.25
rs1538138 6 IBTK –4.98 0.004 0.96 0.42
rs1324183 9 9p23 3.66 0.04 1.09 0.09
rs1409832 9 RXRA/COL5A1 3.31 0.06 1.09 0.07
rs1536478 9 RXRA/COL5A1 4.47 0.004 0.99 0.87
rs1536482 9 RXRA/COL5A1 1.69 0.29 1.04 0.38
rs7044529 9 COL5A1 –6.58 0.003 0.99 0.86
rs1034200 13 AVGR8 2.9 0.08 0.94 0.31
rs2721051 13 FOXO1 4.69 0.04 1.02 0.75
rs2755237 13 FOXO1 1.66 0.40 1.06 0.28
rs1828481 15 AKAP13 0.11 0.94 0.96 0.29
rs4965359 15 LRRK1 2.82 0.07 0.99 0.81
rs6496932 15 PDE8A/AKAP13 2.35 0.22 1.05 0.30
rs7172789 15 AKAP13 0.23 0.88 0.95 0.25
rs930847 15 LRRK1 2.15 0.23 0.97 0.47
rs12447690 16 ZNF469 –5.08 0.001 1.04 0.33
rs9938149 16 ZNF469 3.84 0.01 1.05 0.24
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expected, each copy of the minor allele is associated with
reduced CCT and an increased risk of POAG. A second SNP at
the NTM locus was marginally associated in the low-tension
subset (rs7108536, P¼0.0017, OR¼1.25). The two NTM SNPs
are in high linkage disequilibrium (r2¼0.87). An additional five
SNPs at the CNTNAP4 gene showed suggestive association,
although they did not meet the multiple testing corrected level
of significance (Table 3). The most significant CNTNAP4 SNP
was rs1428758 (P ¼ 0.018, OR ¼ 0.84). The strong linkage
disequilibrium in this region (see Supplementary Material and
Supplementary Fig. S3, http://www.iovs.org/lookup/suppl/
doi:10.1167/iovs.12-9784/-/DCSupplemental) suggests these
signals are probably not independent. The effect of these five
SNPs is also in the expected direction, with each copy of the
minor allele being associated with an increase in CCT and a
protective effect on POAG risk. No SNP was associated with
POAG in the overall dataset or the high-tension subset.
CNTNAP4 and NTM gene expression was evaluated in
human adult and fetal brain, optic nerve, cornea, and sclera
tissues (Fig. 2). CNTNAP4 was shown to be expressed in the
adult brain, optic nerve, and cornea, but no evidence of
CNTNAP4 expression in the adult sclera sample was observed.
Similarly, evidence of CNTNAP4 expression was observed in
the fetal brain, optic nerve, and cornea tissues, but not in the
fetal sclera sample. NTM expression was seen in all of the
tissues examined in both the adult and fetal stage tissues (Fig.
2).
DISCUSSION
CCT is an important quantitative risk factor for POAG, but
whether CCT directly influences POAG susceptibility remains
unknown. One way to improve understanding of this
relationship is to identify genes that are associated with both
traits. This study replicated the association of previously
published CCT genetic variants in a POAG population, and
showed that despite the well established genetic association
observed between these loci and CCT, there was no evidence
that they influence POAG risk. Two POAG candidate genes
were identified, NTM and CNTNAP4, first by association with
CCT, and second by association analysis with POAG risk. These
genes are good biological candidates for future research in the
etiology of POAG.
In our dataset, POAG cases have significantly lower CCT
compared with controls and within the POAG cases, the low-
tension subset has significantly lower mean CCT compared
with the high-tension subset. Consistent with these results,
several studies have suggested CCT is reduced in normal-
tension glaucoma as compared with POAG.18–20 One possible
explanation for this observation is that thinner corneas may be
representative of a thinner, weaker posterior eye structure,
which may increase susceptibility to optic nerve stress caused
by elevated or fluctuating IOP.
In this study, we investigated the effects of previously
published CCT SNPs and replicated the association of
rs12447690 near the ZNF469 gene, an uncharacterized
zinc-finger protein.2–4 Mutations in this gene are known to
cause brittle cornea syndrome, a systemic connective tissue
disorder characterized by a high risk of corneal tearing.21
The association of this SNP with CCT has been replicated in
multiple populations, and there is strong evidence that this
gene is involved with normal CCT variation.2–4 SNPs within
two genes, COL5A1 and IBTK, were previously identified in
multiple population-based CCT studies.3,4,9 There was also
evidence that these SNPs are associated with CCT in this
study’s primarily POAG case population. COL5A1 is a logical
candidate gene for cornea thickness variation as the corneal
stroma is largely composed of regularly arranged collagen
fibers. Mutations in this gene have been identified in Ehlers-
Danlos syndrome patients who have reduced cornea
thickness.22 IBTK was recently identified in a CCT meta-
analysis conducted in a multiethnic Asian population cohort
study.9 This group hypothesized that IBTK may regulate
corneal thickness during developmental stages and embryo-
genesis through its negative regulation of BTK kinase
activity or its effect on nuclear factor-kappa-B (NF-jB)
activation.
The remaining 16 published CCT SNPs did not show
evidence of association with CCT. This may be due to the
limited sample size of the CCT dataset (n¼1117) which had an
estimated 66% power, assuming a minor allele frequency of
0.25 and an effect size of 6.00 D CCT lm/allele,23 to detect
association with CCT. Thus, based on this estimate, false
negative findings for those 16 loci cannot be ruled out.
However, after examining the potential association of all 20
CCT-associated loci with POAG in a larger dataset, there was
no evidence that any of these well established CCT genes
results in increased POAG susceptibility. It is expected that the
overall POAG dataset has greater power to detect genotypic
effects because of the increased sample size (n ¼ 6470),
although the true power of this dataset is unknown because
the putative effect sizes of these loci on POAG risk remain
unknown.
In the CCT GWAS, no SNPS met genome-wide significance
thresholds. As with the replication analysis, this may be due to
a lack of statistical power resulting from sample size limitations
or due to the fact that this study population consists mainly of
POAG cases, which may have different genetic determinants of
CCT than population controls.
To determine if any of the top SNPs identified in the CCT
analysis also influence POAG risk, candidates SNPs were
TABLE 3. Top Ten SNPs Associated with POAG in the Low-Tension Subset
SNP Locus CHR Allele
CCT GWAS (n ¼ 1117) POAG risk (n ¼ 4086)
D lm/Minor Allele P OR P
rs7481514 NTM 11 A –6.89 1.03 3 105 1.28 0.00099
rs7108536 NTM 11 G 6.78 1.00 3 105 1.25 0.0017
rs1428758 CNTNAP4 16 G 6.61 1.74 3 105 0.84 0.018
rs9939043 CNTNAP4 16 A 7.15 2.70 3 106 0.85 0.022
rs6701037 TNN 1 C 6.11 3.31 3 105 0.85 0.024
rs4959388 LY86-AS1 6 G 7.07 1.85 3 105 1.18 0.031
rs1109739 16q12 16 A 8.48 4.13 3 105 0.81 0.038
rs2866710 CNTNAP4 16 G 6.84 1.17 3 105 0.86 0.051
rs2052866 CNTNAP4 16 A 6.51 3.27 3 105 0.86 0.054
rs1428759 CNTNAP4 16 A 6.78 1.53 3 105 0.87 0.072
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selected and tested for association with POAG in the overall
dataset and two subsets, low tension and high tension,
stratified by a history of elevated IOP. Stratification by IOP may
provide a more clinically homogenous population resulting in
reduced genetic heterogeneity within the dataset. In the low-
tension subset of POAG cases, neurotrimin (NTM) was
significantly associated with increased POAG risk and, as
expected, a decrease in CCT. The size of these effects is
consistent with published reports suggesting a decrease of 40
lm of CCT is associated with a 1.7-fold increased risk of
POAG.6 NTM is a member of the immunoglobulin domain-
containing IgLON superfamily of glycosyl-phosphatidylinositol
(GPI)-anchored cell adhesion molecules. NTM can be found in
both membrane-bound and soluble forms and has known
roles in mediating cell-cell interactions and regulating neurite
outgrowth.24–26 It has high homology with the well charac-
terized neuronal cell adhesion molecule (NCAM), which has
also been shown to have a role in neurite outgrowth. NCAM
was found to be constitutively expressed in human corneal
endothelium cells, although the role of neuronal cell adhesion
molecules within the cornea remains unknown.27 Previous
reports found NTM to be expressed during development,
continuing into adulthood, and an abundant expression has
been observed in the ganglion cell layer of the retina.26 It is
possible that NTM plays a role in glaucoma susceptibility by
influencing neuron outgrowth during development. There-
fore, the presence of NTM expression was examined in
relevant tissues from a developing fetus and NTM was shown
to be expressed in the brain, optic nerve, cornea, and sclera
with similar expression observed in the adult sample. An adult
brain sample was included as a positive control since it has
been shown that NTM is expressed primarily in the central
nervous system.27 This expression work provides further
evidence that NTM is a viable candidate for future POAG
research.
Contactin-associated protein-like 4 (CNTNAP4) was also
identified as a candidate gene for glaucoma risk in the low-
tension POAG subset. Although the statistical evidence for
association with this gene is modest, like NTM, it is a neural cell
adhesion molecule and is important in cell-cell interaction
within the nervous system.28 CNTNAP4 is located within a
region linked to keratoconus, a disease defined by the
progressive thinning of the cornea.29 In addition, SNPs within
CNTNAP2, a gene closely related to CNTNAP4, has previously
been associated with pseudoexfoliation glaucoma.30,31
CNTNAP4 was found to be expressed in the brain, optic
nerve, and cornea during development and in adulthood.
Together, NTM and CNTNAP4 suggest that neural cell adhesion
molecules could constitute a novel pathway relating reduced
CCT to POAG risk.
CCT is a readily measurable and highly heritable trait, and
like many other quantitative traits, it is likely to be mediated by
many common loci of modest effect sizes. Rare variants within
the CCT loci may result in profound structural changes in the
cornea, but more common variants might produce the CCT
variation that is observed on a population level. Our results
show that these common variants are not associated with
POAG. Nonetheless, CCT genomics research offers promise to
reveal new insight into the genetic architecture of POAG, as
suggested by the NTM association.
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